ESTRELLA IMMUNOPHARMA, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
ESTRELLA IMMUNOPHARMA, INC. (ESLA) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $2.60 million for the 12-month period ending 2024-06-30, per its 10-K filed 2024-09-27.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2024-09-27
- ESTRELLA IMMUNOPHARMA, INC. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2023-06-30 was $80.88K.
- ESTRELLA IMMUNOPHARMA, INC. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2023-03-31 was -$28.68K.
- ESTRELLA IMMUNOPHARMA, INC. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2022-12-31 was $417.73K, a 453.11% increase year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2022-09-30 was -$72.42K.
- ESTRELLA IMMUNOPHARMA, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $2.60M, a 42.22% decline from fiscal 2023.
- ESTRELLA IMMUNOPHARMA, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $4.50M.
- ESTRELLA IMMUNOPHARMA, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2021 was $52.02K.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 2 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 3 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 3 month as first filed | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 6 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 9 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 9 month as first filed | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | $2.60M 10-K · filed 2024-09-27 | |||||||
| 2023-06-30 | $80.88K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | $52.20K 10-Q · filed 2023-08-01 | $469.93K derived: sum of 3 quarters · filed 2023-08-01 | $4.50M 10-K · filed 2024-09-27 | ||||
| 2023-03-31 | -$28.68K 10-Q · filed 2023-05-18 | $389.05K derived: sum of 2 quarters · filed 2023-08-01 | $316.63K derived: sum of 3 quarters · filed 2023-08-01 | $241.12K derived: sum of 4 quarters · filed 2023-08-01 | ||||
| 2022-12-31 | $417.73K derived: 10-Q 12 month − 10-Q 9 month · filed 2023-08-01 | $345.31K derived: sum of 2 quarters · filed 2023-08-01 | $269.80K derived: sum of 3 quarters · filed 2023-08-01 | $240.13K 10-Q · filed 2023-08-01 | $287.33K 10-K · filed 2023-03-14 | |||
| 2022-09-30 | -$72.42K 10-Q · filed 2022-11-14 | -$147.93K derived: sum of 2 quarters · filed 2022-11-14 | -$177.60K 10-Q · filed 2022-11-14 | -$102.07K derived: sum of 4 quarters · filed 2023-05-18 | ||||
| 2022-06-30 | -$75.51K 10-Q · filed 2022-08-08 | -$105.18K 10-Q · filed 2022-08-08 | -$29.65K derived: sum of 3 quarters · filed 2023-05-18 | -$52.24K derived: sum of 4 quarters · filed 2023-05-18 | ||||
| 2022-03-31 | -$29.66K 10-Q · filed 2023-05-18 | $45.86K derived: sum of 2 quarters · filed 2023-05-18 | $23.28K derived: sum of 3 quarters · filed 2023-05-18 | $22.53K derived: sum of 4 quarters · filed 2023-05-18 | ||||
| 2021-12-31 | $75.52K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $52.94K derived: sum of 2 quarters · filed 2023-03-14 | $52.19K derived: sum of 3 quarters · filed 2023-03-14 | $52.02K 10-K · filed 2023-03-14 | ||||
| 2021-09-30 | -$22.59K 10-Q · filed 2022-11-14 | $22.59K 10-Q · filed 2021-11-10 | -$23.33K derived: sum of 2 quarters · filed 2022-11-14 | -$23.50K 10-Q · filed 2022-11-14 | $23.50K 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | -$747.00 10-Q · filed 2022-08-08 | -$919.00 10-Q · filed 2022-08-08 | ||||||
| 2021-03-31 | -$172.00 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |